Bausch Health Companies (BHC) Receives a Buy from Barclays

In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $28.40.

According to, Prasad is a 4-star analyst with an average return of 16.6% and a 70.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Pacira Pharmaceuticals, and Amag Pharmaceuticals.